Los peligros de los anticonceptivos y su uso en la mujer transexual (página 2)

5. Dahlbäck B, Carlsson M,
Svensson PJ. Familial thrombophilia due to a previously
unrecognised mechanism characterized by poor anticoagulant
response to activated protein C: prediction of a cofactor to
activated protein C. Proc Natl Acad Sci USA 1993; 90:
1004-8.

6. Bloemenkamp KWM, Rosendaal FR,
Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement
by factor V Leiden mutation of risk of deepvein thrombosis
associated with oral contraceptives containing a
thirdgeneration progestagen. Lancet 1995; 346:
1593-6.

7. Blom JW, Doggen CJ, Osanto S,
Rosendaal FR. Old and new risk actors for upper extremity
deep venous thrombosis.JThromb
Haemost2005;3:2471-8.

8. Borrego L, Gil R, Mazuecos A.
Cholesterol embolism to the skin. Clin Exp Dermatol
1992;17:424-6.

9. Boston Collaborative Drug
Surveillance Program. Oral contraceptives and venous
thromboembolic disease, surgically confirmed gall bladder
disease and breast tumours. Lancet 1973; i:
1399-404.

10. Dahlberg PJ, Frecentese DF,
Cogbill TH. Cholesterol embolism: experience with 22
histologically proven cases. Surgery 1989;
105:737-46.

11. Daly E, Vessey MP, Hawkins MM,
Carson JL, Gough P, Marsh S. Risk of venous thromboembolism
in users of hormone replacement therapy. Lancet 1996; 348:
977-80.

12. De Bruijn SF, Stam J,
Vandenbroucke JP. Increased risk of cerebral venous sinus
thrombosis with third-generation oral contraceptives.
Cerebral Venous Sinus Thrombosis Study Group. Lancet 1998;
351:1404.

13. Del Río E,
Vázquez Veiga H, Martín de Hijas C, Gorospe MA,
Sánchez Yus E. Necrosis cutánea por
embolización de cristales de colesterol. Actas
Dermosifiliogr 1993;84:303-6..

14. Dinger JC, Heinemann LA,
Kuhl-Habich D. The safety of a drospirenone-containing oral
contraceptive: final results from the European Active
Surveillance Study on oral contraceptives based on 142,475
women-years of observation.Contraception
2007;75:344-54.

15. Dittrich R, Binder H, Cupisti
S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of
male-to-female transsexuals using gonadotropin-releasing
hormone agonist. Exp Clin Endocrinol Diabetes 2005;
113:586-92.

16. Drife JO. The third generation
pill controversy (continued). BMJ 2001;
323:119-20.

17. Farmer RD, Lawrenson RA,
Thompson CR, Kennedy JG, Hambleton IR. Population-based study
of risk of venous thromboembolism associated with various
oral contraceptives. Lancet 1997; 349: 83-8.

18. Farmer RD, Todd JC, MacRae KD,
Williams TJ, Lewis MA. Oral contraception was not associated
with venous thromboembolic disease in recent study. Br Med J
1998; 316: 1090-1.

19. Fine MJ, Kapoor W, Falanga V.
Cholesterol crystal embolization: a review of 221 cases in
the English literature. Angiology 1987;38:769-84

20. Flory CM. Arterial occlusions
produced by emboli from eroded aortic atheromatous plaques.
Am J Pathol 1945; 21: 549-64.

21. Futterweit
W. Terapia de la transexualidad y las
complicaciones potenciales. Archives of Sexual Behavior
1998; 27: 209-226

22. Gallo MF, Lopez LM, Grimes DA,
Schulz KF, Helmerhorst FM. Combination contraceptives:
effects on weight.Cochrane Database Syst
Rev2008;(4):CD003987.

23. Garcia-Malpartida K,
Martin-Gorgojo A, Rocha M, Gomez-Balaguer M,
Hernandez-Mijares A. Prolactinoma induced by estrogen and
cyproterone acetate in a male-to-female transsexual. Fertil
Steril 2010;94:1097.e13-15

24. Giltay EJ, Gooren LJG. Effect
of sex steroid deprivation/administration on hair growth and
skin sebum production in transsexual males and females. J
Clin Endocrinol Metab 2000;85:2913-21…

25. Gooren L. Hormone treatment of
the adult transsexual patient. Horm Res 2005; 64(suppl
2):31-6.

26. Gooren LJ, Giltay EJ, Bunck
MC. Long-term treatment of transsexuals with cross-sex
hormones: extensive personal experience. J Clin Endocrinol
Metab 2008; 93:19-25.

27. Gooren LJG y Delemarre-van de
Waal. Memo sobre la viabilidad de las intervenciones
endocrinos en los transexuales de menores. Revista de
Psicología y Sexualidad Humana 1996; 8:
69-74

28. Gregersen H. Third generation
oral contraceptives and heritable thrombophilia as risk
factors for non-fatal venous thromboembolism. Thromb Haemost
1998; 79: 28-31.

29. Grodstein F, Stampfer MJ,
Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC,
Hennekens CH. Prospective study of exogenous hormones and
risk of pulmonary embolism in women. Lancet 1996; 348:
983-7.

30. Heinemann LAJ, Dinger JC.
Range of published estimates of venous thromboembolism
incidence in young women. Contraception 2007;
75:328-36.

31. Herings RMC, Urquhart J,
Leufkens HGM. Venous thromboembolism among new users of
different oral contraceptives. Lancet 1999;
354:127-8.

32. Hirsch DR, Mikkola KM, Marks
PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ. Pulmonary
embolism and deep venous thrombosis during pregnancy or oral
contraceptive use: prevalence of factor V Leiden. Am Heart J
1996; 131: 1145-8.

33. Huisman MV, Buller HR, Ten
Cate JW, Vreeken J. Serial impedance plethysmography for
suspected deep venous thrombosis in outpatients. The
Amsterdam General Practitioner Study. N Engl J Med 1986; 314:
823-8.

34. Jick H, Derby LE, Wald Myers
M, Vasilakis C, Newton KM. Risk of hospital admission for
idiopathic venous thromboembolism among users of
postmenopasusal oestrogens. Lancet 1996; 348:
981-3.

35. Jick H, Jick SS, Gurewich V,
Myers MW, Vasilakis C. Risk of idiopathic cardiovascular
death and nonfatal venous thromboembolism in using oral
contraceptives with differing progestagen .Lancet1995;
346:1589-93.

36. Jordan WM. Pulmonary embolism.
Lancet 1961; i: 1146-7.

37. Kamphuisen PW, Eikenboom JCJ,
Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased
levels of factor VIII and fibrinogen in patients with venous
thrombosis are not caused by acute phase reactions. Thromb
Haemost 1999; 81: 680-3.

38. Kemmeren JM, Algra A, Grobbee
DE. Third generation oral contraceptives and risk of venous
thrombosis: meta-analysis. BMJ 2001; 323:131-4.

39. Kemmeren JM, Algra A, Meijers
JC, Bouma BN, Grobbee DE. Effects of second and third
generation oral contraceptives and their respective
progestagens on the coagulation system in the absence or
presence of the factor V Leiden mutation.Thromb Haemost 2002;
87:199-205.

40. Konstantinides S. Acute
pulmonary embolism. N Eng J Med. 2008;359:2804-13

41. Koster T, Blann AD, Briët
E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor
VIII in effect of von Willebrand factor on occurrence of
deep-vein thrombosis. Lancet 1995; 345: 152-5

42. Kuhnz W, Staks T, Jutting G.
Pharmacokinetics of cyproterone acetate and ethinylestradiol
in 15 women who received a combination oral contraceptive
during three treatment cycles.Contraception 1993;
48:557-75.

43. Lachnit-Fixson U. The
development and evaluation of an ovulation inhibitor (DIAne)
containing an antiandrogen.Acta Obstet Gynecol Scand
Suppl1979;88:33-42.

44. Lensing AW, Prandoni P,
Brandjes D, Huisman PM, Vigo M, Tomasella G, Krekt J, Wouter
TC, Huisman MV, Buller HR. Detection of deep-vein thrombosis
by real-time B-mode ultrasonography. N Engl J Med 1989; 320:
342-5.

45. Lidegaard O, Edström B,
Kreiner S. Oral contraceptives and venous thromboembolim. A
case-control study.Contraception 1998; 57:291-301.

46. Lopez LM, Kaptein A,
Helmerhorst FM. Oral contraceptives containing drospirenone
for premenstrual syndrome.Cochrane Database Syst Rev
2009;(2):CD006586.

47. Martinelli I, Taioli E,
Bucciarelli P, Akhavan S, Mannucci PM. Interaction between
the G20210A mutation of the prothrombin gene and oral
contraceptive use in deep vein thrombosis. Arterioscler
Thromb Vasc Biol 1999; 19: 700-3.

48. McNeill EJM. Management of the
transgender voice. J Laryngol Otology 2006;
120:521-3.

49. Middeldorp S, Meijers JC, Van
den Ende AE, Van Enk A, Bouma BN, Tans G, et al. Effects on
coagulation of levonorgestrel- and desogestrel-containing low
dose oral contraceptives: a cross-over study. Thromb Haemost
2000; 84:4-8.

50. Moolenaar W, Lamers CB.
Cholesterol crystal embolization in the Netherlands. Arch
Intern Med 1996;156:653-7

51. Moore E, Wisniewski A, Dobs A.
Endocrine treatment of transsexual people: a review of
treatment regimens, outcomes, and adverse effects. J Clin
Endocrinol Metab 2003; 88:3467- 73.

52. Muhn P, Fuhrmann U,
Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone:
a novel progestogen with antimineralocorticoid and
antiandrogenic activity.Ann N Y Acad Sci1995; 761:
311-35.

53. Naess IA, Christiansen SC,
Romundstad P, Cannegieter SC, Rosendaal FR,
Hammerstrøm J. Incidence and mortality of venous
thrombosis: a population-based study.J Thromb Haemost 2007;
5:692-9.

54. Oelkers W, Foidart JM,
Dombrovicz N, Welter A, Heithecker R. Effects of a new oral
contraceptive containing an antimineralocorticoid ,
drospirenone, on the renin-aldosterone system, body weight,
blood pressure, glucose tolerance, and lipid metabolism.J
Clin Endocrinol Metab1995;80:1816-21.

55. Poort SR, Rosendaal FR,
Reitsma PH, Bertina RM. A common genetic variation in the
3"-untranslated region of the prothrombin gene is associated
with elevated plasma prothrombin levels and an increase in
venous thrombosis. Blood 1996; 88: 3698-703.

56. Porter JB. Oral contraceptives
and nonfatal vascular disease — recent experience. Obstet
Gynecol 1982; 59: 299-302.

57. Prasad RN, Koh SC, Viegas OA,
Ratnam SS. Effects on hemostasis after two-year use of low
dose combined oral contraceptives with gestodene or
levonorgestrel. Clin Appl Thromb Hemost 1999;
5:60-70.

58. Records Unit and Research
Advisory Service of the Royal College of General Practioners.
Oral contraception and thrombo-embolic disease. J R Coll Gen
Pract 1967; 13: 267-79.

59. Revenga Arranz F,
García Bracamonte B, Quintana Martínez I,
Rodríguez Peralto JL, Iglesias Díez L.
Embolismo de colesterol con afectación cutánea:
presentación de tres casos. Actas Dermosifiliogr
1996;87:269-71

60. Rintelen C, Mannhalter C,
Ireland H, Lane DA, Knobl P, Lechner K, Pabinger I. Oral
contraceptives enhance the risk of clinical manifestation of
venous thrombosis at a young age in females homozygous for
factor V Leiden. Br J Haematol 1996; 93: 487-90.

61.  Ronde H, Bertina RM.
Laboratory diagnosis of APC-resistance: a critical evaluation
of the test and the development of diagnostic criteria.
Thromb Haemost 1994; 72: 880-6.

62. Rosendaal FR, Helmerhorst FM,
Vandenbroucke JP. Oral contraceptives, hormone replacement
therapy and thrombosis Thromb Haemost 2001;
86:112-23.

63. Rosendaal FR, Koster T,
Vandenbroucke JP, Reitsma PH. High risk of thrombosis in
patients homozygous for factor V Leiden (activated protein C
resistance). Blood 1995; 85: 1504-8.

64. Rosing J, Curvers J, Tans G.
Oral contraceptives, thrombosis and haemostasis. Eur J Obstet
Gynecol Reprod Biol 2001; 95:193-7.

65. Rosing J, Middeldorp S,
Curvers J, Christela M, Thomassen LG, Nicolaes GA, et al.
Low-dose oral contraceptives and acquired resistance to
activated protein C: a randomised cross-over study. Lancet
1999; 354:2036-40.

66. Rosing J, Tans G, Nicolaes GA,
Thomanssen MC, Van der Oerle R, Van der Ploeg PM. Oral
contraceptives and venous trombosis: different sensitivies to
activated protein C in women using second-and third
generation oral contraceptives. Br J Haematol 1997;
97:233-8.

67. Royal College of General
Practioners" Oral Contraception Study. Oral contraceptives,
venous thrombosis, and varicose veins. J R Coll Gen Pract
1978; 28: 393-9.

68. Sánchez R, Martinez O.
Guía práctica en anticoncepción oral
basada en la evidencia. Madrid: Emisa, 2003.

69. Sapp AV, Lindbloom EJ. Do
third-generation oral contraceptives (OCs) increase the risk
of venous thrombosis? J Fam Pract 2001; 50:893.

70. Sartwell PE, Masi AT, Arthes
FG, Greene GR, Smith HE. Thromboembolism and oral
contraceptives: an epidemiological case-control study. Am J
Epidemiol 1969; 90: 365-80.

71. Schlatterer K, Yassouiridis A,
von Werder K, Polonia D, Kemper J, Stalla GK. Un
estudio de seguimiento a la estimación de la eficacia
de una terapia de sustitución hormonal de
género cruzado en pacientes
transexuales. Archives of Sexual Behavior, 1998; 27:
475-492…

72. Seeger JD, Loughlin J, Eng PM,
Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in
women taking ethinylestradiol/ drospirenone and other oral
contraceptives.Obstet Gynecol 2007; 110:587-93.

73. Spitzer WO, Lewis MA,
Heinemann LA, Thorogood M, MacRae KD. Third generation oral
contraceptives and risk of venous thromboembolic disorders:
an international case-control study. Transnational Research
Group on Oral Contraceptives and the Health of Young Women.
BMJ 1996; 312:83-8.

74. Spitzer WO. El acetato de
ciproterona con etinilestradiol como un factor de riesgo de
tromboembolismo venoso: una evaluación
epidemiológica. J Obstet Gynaecol Can. 2003
Dec;25(12):1011-8.

75. Stegeman BH, deBastos M,
Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen
T, Dekkers OM. Different combined oral contraceptives and the
risk of venous thrombosis: systematic review and network
meta-analysis. BMJ 2013; 347: f5298.

76. Stolley PD, Tonascia JA,
Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis
with low-estrogen oral contraceptives. Am J Epidemiol 1975;
102: 197-208.

77. Tans G, Curvers J, Middeldorp
S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized
cross-over study on the effects of levonorgestrel- and
desogestrel-containing oral contraceptives on the
anticoagulant pathways. Thromb Haemost 2000;
84:15-21.

78. Tans G, van Hylckama Vlieg A,
Thomassen MCLGD, Curvers J, Bertina RM, Rosing J, et al.
Activated protein C resistance determined with a thrombin
generation-based test predicts for venous thrombosis in men
and women.Br J Haematol2003; 122:465-70.

79. The Coronary Drug Project
Research Group. The Coronary Drug Project. Findings leading
to discontinuation of the 2.5-mg day estrogen group. JAMA
1973; 226: 652-7.

80. Thorogood M, Mann J, Murphy M,
Vessey M. Risk factors for fatal venous thromboembolism in
young women: a case-control study. Int J Epidemiol 1992; 21:
48-52

81. Van Haarst EP, Newling ARD,
Gooren LJG, Asscheman H, Prenger. DM
metastásico carcinoma de próstata en un
transexual de hombre a mujer. British Journal of
Urology, 1998; 81: 776

82. Van Kesteren P, Lips P, Gooren
LJG, Asscheman H, Megens J (1998) A largo plazo
de seguimiento de la densidad mineral ósea en los
transexuales tratados con hormonas del sexo
opuesto. Clinical Endocrinology 48: 347-354

83. Van Kesteren P, Megens JAJ,
Asscheman H, efectos. Gooren LJG secundarios de
la administración hormonal del sexo en
transexuales. Clinical Endocrinology, 1997; 47:
337-342

84. Van Kesteren PJ, Asscheman H,
Megens JA, Gooren LJ. Mortality and morbidity in transsexual
subjects treated with cross-sex hormones. Clin Endocrinol
(Oxf) 1997; 47: 337-42..

85. Van Vliet HA, Frolich M,
Christella M, Thomassen MCLGD, Doggen CJM, Rosendaal FR, et
al. Association between sex hormone-binding globulin levels
and activated protein C resistance in explaining the risk of
thrombosis in users of oral contraceptives containing
different progestogens.Hum Reprod 2005; 20:563-8.

86. Van Vliet HA, Winkel TA, Noort
I, Rosing J, Rosendaal FR. Prothrombotic changes in users of
combined oral contraceptives containing drospirenone and
cyproterone acetate.J Thromb Haemost 2004;
2:2060-2.

87. Vandenbroucke JP, Koster T,
Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased
risk of venous thrombosis in oral-contraceptive users who are
carriers of factor V Leiden mutation. Lancet 1994; 344:
1453-7.

88. Vasilakis C, Jick SS, Jick H.
The risk of venous thromboembolism in users of postcoital
contraceptive pills. Contraception 1999; 59:
79-83.

89. Vessey MP, Doll R.
Investigation of relation between use of oral contraceptives
and thromboembolic disease. Br Med J 1968; 2:
199-205.

90. Vessey MP, Doll R.
Investigation of relation between use of oral contraceptives
and thromboembolic disease: a further report. Br Med J 1969;
2: 651-7.

91. World Health Organization
Collaborative Study of Cardiovascular Disease and Steroid
Hormone Contraception. Venous thromboembolic disease and
combined oral contraceptives: results of international
multicentre case-control study. Lancet 1995;
346:1575-82.

92. World Health Organization
Collaborative Study of Cardiovascular Disease and Steroid
Hormone Contraception. Effect of different progestagens in
low oestrogen oral contraceptives on venous thromboembolic
disease. Lancet 1995; 346:1582-8.

93. World Health Organization.
Cardiovascular disease and steroid hormone contraception.
Report of a WHO Technical Report Series Geneva: WHO,
1998

94. Writing Group for the Women's
Health Initiative Investigators. Risks and benefits of
estrogen plus progestin in healthy postmenopausal women. JAMA
2002;288:321-33.

95. Yahyaoui R, Esteva I,
Haro-Mora JJ, et al. Effect of long-term administration of
cross-sex hormone therapy on serum and urinary acid in
transsexual persons. J Clin Endocrinol Metab 2008;
93:2230-3.